$171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024
The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives
BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2024.
Full Year 2024 Financial Results
As of December 31, 2024 and December 31, 2023, the company had cash, cash equivalents and marketable securities totaling $171.4 million and $303.5 million, respectively.
Research and development expenses for the fourth quarter 2024 were $9.2 million and $78.2 million for the full year ended December 31, 2024, compared to $33.3 for the fourth quarter 2023 and $106.7 million for the full year ended December 31, 2023. The decrease was primarily due to lower clinical development costs.
General and administrative expenses for the fourth quarter 2024 were $6.1 million and $28.8 for the full year ended December 31, 2024, compared to $7.0 million for the fourth quarter 2023 and $26.7 for the full year ended December 31, 2023. The year over year increase was primarily due to higher personnel related costs.
Other income for the fourth quarter 2024 was $2.2 million and $8.0 for the full year ended December 31 2024, compared to $3.3 million for the fourth quarter 2023 and $9.8 million for the full year ended December 31, 2023. The decrease was primarily driven by interest expense incurred on the repayment of the term loan facility during 2024.
Net loss for the fourth quarter 2024 was $33.9 million and $147.3 for the year ended December 31, 2024, compared to $37.0 million for the fourth quarter 2023 and $123.6 for the full year ended December 31, 2023.
About HilleVax
HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Globally, norovirus is estimated to result in over approximately 700 million cases of AGE and 200,000 deaths per year, resulting in over $4 billion in direct health system costs and $60 billion in societal costs per year. The burden of norovirus falls disproportionately on young children and older adults. For more information about HilleVax, visit the company’s website at http://www.HilleVax.com.
Forward-Looking Statements
The Company cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the Company’s current beliefs and expectations and include, but are not limited to: the timing and scope of any workforce reductions, the amount and timing of the related charges and costs, and intended objectives and benefits of a workforce reduction; and the Company’s plan to explore the potential for continued development of its norovirus vaccine candidates as well as business development-related activities for these vaccine candidates. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in the Company’s business, including, without limitation: the preliminary nature of the Company’s estimates of the charges and cash expenditures to be incurred in connection with the recent workforce reduction; the Company may not realize the benefits expected from the workforce reduction, including the Company’s ability to conserve cash; the Company’s ability to retain key personnel; to date the Company has depended primarily on the success of HIL-214, and the Company may be unable to identify a viable development path forward for its vaccine candidates; the Company may be unable to secure partnerships or other strategic collaborations on acceptable terms or at all; and other risks described in the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Shane Maltbie IR@hillevax.com +1-617-213-5054
HilleVax, Inc. Condensed Consolidated Statement of Operations Data (in thousands, except share and per share data) (unaudited)
Three Months Ended
Year Ended
December 31,
December 31,
2024
2023
2024
2023
Operating expenses:
Research and development
$
9,199
$
33,258
$
78,172
$
106,683
In-process research and development
—
—
15,325
—
General and administrative
6,138
7,033
28,787
26,662
Restructuring and impairment charges
20,814
—
33,007
—
Total operating expenses
36,151
40,291
155,291
133,345
Loss from operations
(36,151
)
(40,291
)
(155,291
)
(133,345
)
Total other income
2,204
3,331
8,024
9,779
Net loss
$
(33,947
)
$
(36,960
)
$
(147,267
)
$
(123,566
)
Net loss per share, basic and diluted
$
(0.68
)
$
(0.78
)
$
(3.00
)
$
(3.04
)
Weighted-average shares of common stock outstanding, basic and diluted
49,583,518
47,557,423
49,153,125
40,598,482
HilleVax, Inc. Condensed Consolidated Balance Sheet Data (in thousands) (unaudited)
